Cadrenal Therapeutics (CVKD) Competitors $14.13 +0.36 (+2.61%) Closing price 10/24/2025 03:52 PM EasternExtended Trading$13.89 -0.24 (-1.70%) As of 10/24/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. CRDL, ENTX, EXOZ, COYA, IMMX, ATNF, ATYR, QNCX, ORMP, and SCLXShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Cardiol Therapeutics (CRDL), Entera Bio (ENTX), eXoZymes (EXOZ), Coya Therapeutics (COYA), Immix Biopharma (IMMX), 180 Life Sciences (ATNF), aTyr Pharma (ATYR), Quince Therapeutics (QNCX), Oramed Pharmaceuticals (ORMP), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Its Competitors Cardiol Therapeutics Entera Bio eXoZymes Coya Therapeutics Immix Biopharma 180 Life Sciences aTyr Pharma Quince Therapeutics Oramed Pharmaceuticals Scilex Cadrenal Therapeutics (NASDAQ:CVKD) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends. Does the media favor CVKD or CRDL? In the previous week, Cardiol Therapeutics had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.95 beat Cardiol Therapeutics' score of 0.50 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cadrenal Therapeutics Positive Cardiol Therapeutics Neutral Which has more risk & volatility, CVKD or CRDL? Cadrenal Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Do insiders and institutionals believe in CVKD or CRDL? 7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, CVKD or CRDL? Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.59Cardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.50 Is CVKD or CRDL more profitable? Cardiol Therapeutics' return on equity of -232.26% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -265.37% -196.38% Cardiol Therapeutics N/A -232.26%-158.19% Do analysts prefer CVKD or CRDL? Cadrenal Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 126.47%. Cardiol Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 572.27%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryCardiol Therapeutics beats Cadrenal Therapeutics on 10 of the 14 factors compared between the two stocks. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.18M$3.42B$6.24B$10.69BDividend YieldN/A2.27%5.72%4.82%P/E Ratio-1.5927.6331.3430.83Price / SalesN/A461.42562.89174.99Price / CashN/A46.1437.0861.44Price / Book3.3910.4012.056.61Net Income-$10.65M-$52.83M$3.33B$277.10M7 Day Performance3.67%2.10%1.93%2.56%1 Month Performance-0.49%12.33%7.77%3.77%1 Year Performance-10.51%14.14%56.40%33.01% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics3.2632 of 5 stars$14.13+2.6%$32.00+126.5%-15.7%$28.18MN/A-1.594Analyst ForecastCRDLCardiol Therapeutics2.1945 of 5 stars$1.24+17.6%$8.00+547.8%-36.7%$107.13MN/A-3.6020News CoverageAnalyst ForecastHigh Trading VolumeENTXEntera Bio2.1136 of 5 stars$2.33-5.8%$10.00+329.9%+22.0%$106.21M$180K-8.9520News CoveragePositive NewsAnalyst ForecastEXOZeXoZymes0.3107 of 5 stars$12.59+3.2%N/AN/A$105.63M$70K0.0029News CoverageAnalyst ForecastCOYACoya Therapeutics2.7809 of 5 stars$6.32-1.5%$16.20+156.5%-36.4%$105.12M$423.45K-5.076News CoverageAnalyst ForecastGap DownIMMXImmix Biopharma3.3859 of 5 stars$3.13+1.8%$8.00+156.0%+127.0%$103.73MN/A-4.089Positive NewsAnalyst ForecastHigh Trading VolumeATNF180 Life SciencesN/A$17.12+1.9%N/AN/A$103.39MN/A-1.147Gap UpATYRaTyr Pharma3.06 of 5 stars$1.05+2.5%$23.25+2,124.9%-70.2%$103.38M$230K-1.3253Trending NewsAnalyst ForecastQNCXQuince Therapeutics3.5591 of 5 stars$1.81-2.2%$8.14+349.9%+47.9%$97.22MN/A-1.6660Analyst ForecastORMPOramed Pharmaceuticals0.549 of 5 stars$2.36+2.8%N/A+1.3%$96.56M$1.34M-6.7310News CoverageAnalyst ForecastSCLXScilex2.587 of 5 stars$13.83-1.8%$630.00+4,455.3%-47.8%$96.24M$44.24M-0.4880Positive NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies CRDL Competitors ENTX Competitors EXOZ Competitors COYA Competitors IMMX Competitors ATNF Competitors ATYR Competitors QNCX Competitors ORMP Competitors SCLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
